General practitioners hold the key to expanding access to treatment
Hepatitis C virus (HCV) is an important cause of morbidity and mortality in Australia. More than 200 000 people are estimated to be living with chronic HCV infection, with over 80% of these infections resulting from unsafe injecting drug use. About 10 000 new infections occur annually, although incidence is thought to be declining.1 Following primary HCV infection, persistent viraemia and chronic hepatitis occurs in 50%–80% of patients; after 20 years approximately 7% develop cirrhosis, and a small proportion of these patients develop hepatocellular carcinoma.1
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Ministerial Advisory Committee on AIDS, Sexual Health and Hepatitis: Hepatitis C Sub-Committee. Hepatitis C Virus Projections Working Group: estimates and projections of the hepatitis C virus epidemic in Australia 2006. Sydney: National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 2006.
- 2. Kim AI, Saab S. Treatment of hepatitis C. Am J Med 2005; 118: 808-815.
- 3. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-1313.
- 4. Abbott T. Australians with hepatitis C gain easier access to treatments [press release]. 20 Feb 2006. www.health.gov.au/internet/ministers/publishing.nsf/Content/6E130AAD737A22FFCA25711B000E9BB6/$File/abb019.pdf (accessed Jul 2009).
- 5. National Centre in HIV Epidemiology and Clinical Research. HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2009. Sydney: NCHECR, University of New South Wales, 2009.
- 6. Hallinan R, Byrne A, Dore GJ. Harm reduction, hepatitis C and opioid pharmacotherapy: an opportunity for integrated hepatitis C virus-specific harm reduction. Drug Alcohol Rev 2007; 26: 437-443.
- 7. Dev A, Sievert W. A survey of Australian general practice management of hepatitis C-infected patients from non-English-speaking backgrounds. J Gastroenterol Hepatol 2002; 17: 295-300.
- 8. Gupta L, Shah S, Ward JE. Educational and health service needs of Australian general practitioners in managing hepatitis C. J Gastroenterol Hepatol 2006; 21: 694-699.
- 9. Wang J, Guy R, Hellard M. The Victorian hepatitis C education program for GPs: an evaluation. Aust Fam Physician 2009; 38: 749-752.
- 10. Gifford SM, O’Brien ML, Bammer G, et al. Australian women’s experiences of living with hepatitis C virus: results from a cross-sectional survey. J Gastroenterol Hepatol 2003; 18: 841-850.
- 11. Gifford SM, O’Brien ML, Smith A, et al. Australian men’s experiences of living with hepatitis C virus: results from a cross-sectional survey. J Gastroenterol Hepatol 2005; 20: 79-86.
- 12. van der Poel CL, Cuypers HT, Reesink HW. Hepatitis C virus six years on. Lancet 1994; 344: 1475-1479.
- 13. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
Margaret Hellard receives funding from the National Health and Medical Research Council for a Senior Research Fellowship.